Articles

Data from phase 2 trials involving lurbinectedin and irinotecan have been analyzed for patients with relapsed small cell lung cancer (SCLC) who have had a chemotherapy-free interval of >30 days. Read More ›

A pooled analysis of 5-year clinical outcomes from 2 early-phase trials, NEOSTAR and CA209-159, showed promising long-term clinical effectiveness in patients with resectable non-small cell lung cancer (NSCLC). Read More ›

At the 2024 European Hematology Association Annual Congress, researchers presented the multilineage and safety results from the COMMANDS trial of transfusion-dependent, erythropoiesis-stimulating agent–naïve patients with very low-, low-, or intermediate-risk myelodysplastic syndromes. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers analyzed the relationship between hemoglobin and the quality of life of transfusion-dependent patients with lower-risk myelodysplastic syndromes receiving luspatercept or epoetin alfa. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers presented the real-world dose escalation of luspatercept and its outcomes among patients with lower-risk myelodysplastic syndromes. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers explored the emotional, physical, and financial burden experienced by patients with transfusion-dependent lower-risk myelodysplastic syndromes based in North America and Europe. Read More ›

Researchers presented a model to compare treatment outcomes for patients with lower-risk myelodysplastic syndromes who rely on red blood cell transfusions starting from first-line treatment initiation throughout their lifetime. Read More ›

At the ASCO 2024 Annual Meeting, researchers presented the differences in time toxicity among patients undergoing myelodysplastic syndromes/neoplasms with oral hypomethylating versus parenteral hypomethylating agents. Read More ›

At the ASCO 2024 Annual Meeting, researchers presented oral azacitidine’s safety and efficacy results in patients with low-/intermediate-risk myelodysplastic syndromes, as documented in the ASTREON trial. Read More ›

At the ASCO 2024 Annual Meeting, researchers summarized the most recent results from the phase 2 study of IMM01 in combination with azacitidine, a first-line treatment for adults with higher-risk myelodysplastic syndromes. Read More ›